Interventional treatments involve small infiltrations with corticosteroids, surgeries to release fistulas (deroofing) or large flaps or grafts for the treatment of larger defects.1821 HS was deprived of biological or small molecule treatments until 2015, when the EMA and the FDA approved the use of adalimumab for the treatment of severe HS refractory to other treatments.22,23 With the involvement of tumor necrosis factor alpha (TNF-alpha) in its pathogenesis, new cytokines and molecular targets have been progressively studied for the treatment of severe HS, including IL-1, IL-17, IL-23, IL-36, complement 5a (C5a), C5a receptor, the Janus kinase pathway (JAK) or phosphodiesterase 4 (PDE4).2429 A graphic summary of the pathophysiology of HS can be found in Fig
Drug efficacy Antineoplastic drugs typically require certain conditions to exert optimal therapeutic effects
Sikiric, P., et al., A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine
An animal study, for example, demonstrated that AOD-9604 could assist with weight loss in genetically obese rats and mice
